Prolyl hydroxylase EGLN3 (EGLN3)
Homo sapiens — UniProt Q9H6Z9
Data last refreshed: (UniProt release unknown)
Key facts
Prolyl hydroxylase EGLN3 (EGLN3) is a protein from Homo sapiens identified by UniProt accession Q9H6Z9, 239 residues long. MolForge cross-references it against 6 known binders and 230 disease associations.
- UniProt accession: Q9H6Z9; gene symbol EGLN3.
- Organism: Homo sapiens.
- Length: 239 amino acids.
- Approved drugs acting on it (DrugCentral): Daprodustat, Vadadustat, Enarodustat, Molidustat and Roxadustat.
- Top disease associations (Open Targets): anemia (phenotype), chronic kidney disease and erythrocyte count.
- 3D structure: AlphaFold model available.
Target properties
| Protein name | Prolyl hydroxylase EGLN3 |
|---|---|
| UniProt accession | Q9H6Z9 |
| Gene | EGLN3 |
| Organism | Homo sapiens |
| Length | 239 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | — |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). Approved drug exists
| Druggability tier | MEDIUM |
|---|---|
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Approved drugs acting on this target (5)
Approved drugs whose DrugCentral mechanism of action is this protein, most potent first.
Disease associations (230)
Diseases linked to this target (Open Targets).
- anemia (phenotype) · score 0.58
- chronic kidney disease · score 0.56
- erythrocyte count · score 0.48
- hemoglobin measurement · score 0.48
- hematocrit · score 0.46
- myelodysplastic syndrome · score 0.40
- anemia · score 0.37
- red blood cell density measurement · score 0.37
- mean corpuscular hemoglobin concentration · score 0.35
- glaucoma · score 0.33
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|---|---|---|---|
| AF-Q9H6Z9-F1 | alphafold | PREDICTED | 91.02 | — |
Experimental structures are not indexed in MolForge yet — search RCSB PDB for Q9H6Z9.
Amino-acid sequence (239 residues)
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
Which approved drugs target EGLN3?
DrugCentral lists 5 approved drugs whose mechanism of action is EGLN3: Daprodustat, Vadadustat, Enarodustat, Molidustat and Roxadustat.
Which diseases are associated with EGLN3?
The strongest Open Targets associations for EGLN3 are anemia (phenotype), chronic kidney disease, erythrocyte count, hemoglobin measurement and hematocrit.
How long is the EGLN3 protein?
The Homo sapiens EGLN3 protein (UniProt Q9H6Z9) is 239 amino acids long.
Browse: Targets: E · all protein targets A–Z · drugs A–Z.
Sources
- UniProtKB Q9H6Z9 — name, gene, function, sequence, keywords (CC BY 4.0)
- AlphaFold DB Q9H6Z9 — predicted 3D structure (CC BY 4.0)
- DrugCentral — approved drugs and mechanism-of-action links (CC BY-SA 4.0)
- Open Targets Platform — disease associations and tractability (CC0)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.